Collplant Biotechnologies

Yahoo Finance • last month

CollPlant Biotechnologies Ltd (NASDAQ:CLGN) Q2 2025 Earnings Fall Significantly Short of Estimates

CollPlant Biotechnologies Ltd (NASDAQ:CLGN [https://www.chartmill.com/stock/quote/CLGN]) reported second-quarter financial results for 2025 that fell significantly short of analyst expectations, triggering a negative market reaction in pre... Full story

Yahoo Finance • last month

CollPlant Biotechnologies Non-GAAP EPS of -$0.33, revenue of $2.23M misses by $0.31M

* CollPlant Biotechnologies press release [https://seekingalpha.com/pr/20206173-collplant-biotechnologies-reports-2025-second-quarter-financial-results-and-provides] (NASDAQ:CLGN [https://seekingalpha.com/symbol/CLGN]): Q2 Non-GAAP EPS o... Full story

Yahoo Finance • 2 months ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

REHOVOT, Israel, Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue r... Full story

Yahoo Finance • 3 months ago

CollPlant files to sell 1.27M ordinary shares for holders

* CollPlant (NASDAQ:CLGN [https://seekingalpha.com/symbol/CLGN]) filed to sell 1.27M ordinary shares for holders. * Filing [https://seekingalpha.com/filing/10106901] MORE ON COLLPLANT BIOTECHNOLOGIES * CollPlant shares rise on expa... Full story

Yahoo Finance • 4 months ago

CollPlant Biotechnologies shares slide after announces capital raise $3.6M through registered direct offering

CollPlant Biotechnologies (NASDAQ:CLGN [https://seekingalpha.com/symbol/CLGN]) said Friday that it will undertake a registered direct offering and concurrent private placement [https://seekingalpha.com/pr/20121085-collplant-biotechnologies... Full story

Yahoo Finance • 3 years ago

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharm... Full story